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CLONING AND GENERATION OF A MURINE MODEL OF GLYCEROL-3-
PHOSPHATE DEHYDROGENASE 1-LIKE GENE, A CAUSE OF THE BRUGADA 
SYNDROME?
      Michael David Michalec, M.S.
      University of Pittsburgh, 2007 
Cardiovascular disease (CVD) is a major public health concern. It is the Nation’s leading 
killer for both men and women of all racial and ethnic groups. CVD is responsible for about 1 
million deaths each year in the United States. Health-related behaviors such as smoking, lack of 
physical activity and poor nutritional habits, as well as, many genetic factors contribute to its 
high incidence. Many of the genetic factors have been linked to high cholesterol, high blood 
pressure, obesity, diabetes and cardiac arrhythmias leading to stroke or sudden cardiac death. 
CVDs associated with ventricular arrhythmias are most severe. Among these is the Brugada 
syndrome also known as Sudden Unexpected Death Syndrome or SUDS. In 1992, the Brugada 
syndrome was classified as a distinct clinical heart condition characterized by an apparent right 
bundle branch block and ST segment elevation in the right precordial electrocardiogram (ECG) 
leads V -V1 3. It is the most common cause of sudden cardiac death in South Asian men who are 
less than 50 years of age and have no underlying cardiac disease. Currently the only effective 
treatment for the disease is the Implantable Cardioverter Defibrillator (ICD) surgically placed in 
the patient’s chest. The genetic basis for the Brugada syndrome has been linked to mutations in 
the SCN5A gene that codes for the alpha-subunit of the cardiac sodium channel. Recently, a 
missense mutation has been discovered in a novel gene that causes the Brugada syndrome. The 
novel gene is named the Glycerol-3-phosphate Dehydrogenase 1-Like (GPD1L) gene. 
Preliminary studies suggest a direct relationship between the GPD1L mutation and a decrease in 
cellular sodium current. Transgenic murine models are useful tools for understanding the 
molecular function of novel genes. Transgenic constructs of the wild type and mutant GPD1L 
gene were generated and used for the production of transgenic mice. The mice were produced by 
pronuclear injection at the University of Pittsburgh Transgenic facility. These mice will provide 
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an in vivo approach to study the GPD1L gene and create the first Brugada syndrome mouse 
model for cardiovascular disease studies. 
 
 
 v 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS ....................................................................................................XI 
PREFACE.................................................................................................................................XIII 
1.0 INTRODUCTION........................................................................................................ 1  
2.0 BACKGROUND .......................................................................................................... 4  
2.1 TRANSGENIC MOUSE MODELS................................................................... 4  
2.2 MOLECULAR CLONING................................................................................. 6  
3.0 MATERIAL AND METHODS................................................................................. 10  
3.1 PLASMID VECTORS....................................................................................... 10  
3.2 PREPARATION OF BACTERIAL CULTURE MEDIA AND PLATES ... 11  
3.3 TRANSFORMATION OF CHEMICALLY-COMPETENT CELLS AND 
                 ISOLATION OF PLASMID DNA................................................................... 12 
3.4 AUTOMATED DNA SEQUENCING ............................................................. 14  
3.5 MUTAGENESIS................................................................................................ 16  
3.6 RESTRICTION ENZYME DIGESTS ............................................................ 18  
3.7 LIGATION AND TRANSFORMATION OF GPD1L INSERT AND 
                 PLASMID DIGESTED PRODUCTS:............................................................. 21 
3.8 PHENOL/CHLOROFORM EXTRACTION ................................................. 22  
3.9 ETHANOL PRECIPITATION ........................................................................ 23  
 vi 
3.10 KLENOW REACTION .................................................................................... 23  
3.11 CIP (CALF INTESTINAL/ ALKALINE PHOSPHATASE) REACTION . 24  
4.0 RESULTS ................................................................................................................... 25  
4.1 CONSTRUCTION OF THE PBLUESCRIPTR/GPD1L CLONE ............... 25  
4.2 MUTAGENESIS OF PBLUESCRIPT/GPD1L WILD TYPE CLONE....... 26  
4.3 CREATION OF PBK-CMV/GPD1L INTERMEDIATE CLONE............... 28  
 a-MHCpBluescript II SK+ /GPD1L CLONE CONSTRUCT4.4 ..................31  
4.4.1 First round:.................................................................................................. 31  
4.4.2 Second round:.............................................................................................. 32  
4.4.3 Third round:................................................................................................ 33  
4.5 PRONUCLEAR INJECTION.......................................................................... 40  
5.0 DISCUSSION ............................................................................................................. 44  
BIBLIOGRAPHY....................................................................................................................... 47 
 vii 
 LIST OF TABLES 
 
Table 1 GPD1L Primers used for DNA sequencing..................................................................... 14 
Table 2 Conditions for Restriction Enzyme digests. .................................................................... 19 
Table 3 PCR primers for transgene conformation: F & #1: 500 bp; F & #2: 800 bp................... 40 
 viii 
LIST OF FIGURES 
 
Figure 1 Tissue specific expression of GPD1L gene...................................................................... 3 
Figure 2 Diagram of Molecular cloning. ........................................................................................ 8 
Figure 3 Transgenic construct flow chart summarizing the cloning process.................................. 9 
Figure 4 α- MHCpBluescript II SK+ plasmid. ............................................................................. 11 
Figure 5 Construction of pBluescriptR/GPD1L clone.................................................................. 25 
Figure 6 Site-directed mutagenesis of the pBluescriptR/GPD1L wild type clone. ...................... 27 
Figure 7 Sequence comparison of wild type and mutant GPD1L. ............................................... 27 
Figure 8 Construction of pBK-CMV/GPD1L clone (~8127 bp). ................................................. 29 
Figure 9 Gel picture of pBluescriptR/GPD1L clone and EcoRI/BamHI digest. .......................... 29 
Figure 10 Restriction analysis of pBK-CMV clone...................................................................... 30 
Figure 11 Compatible overhangs for Sal I and Xho I................................................................... 32 
Figure 12 Illustration of BSTUI digest. ........................................................................................ 34 
Figure 13 Creation of final construct. ........................................................................................... 35 
Figure 14 α-MHCpBluescript II SK+GPD1L clone. .................................................................... 35 
Figure 15 Gel showing the creation of WT1 and MUT1.............................................................. 36 
Figure 16  Gel showing the creation of WT2 and MUT2............................................................. 37 
Figure 17 Gel picture showing Cla I linearized α-MHCpBluescript II SK+ plasmid .................. 37 
 ix 
Figure 18 Not I digestion .............................................................................................................. 38 
Figure 19 Final construct after Not 1 RE digest. .......................................................................... 38 
Figure 20 Mutagenesis of α-MHCpBluescript II SK+ /GPD1L wild type clone. ........................ 39 
Figure 21 PCR of mouse tail DNA using the forward and reverse #1 ......................................... 41 
Figure 22 Second pronuclear injection test PCR of wild type...................................................... 42 
Figure 23 Mutant PCR.................................................................................................................. 43 
 x 
LIST OF ABBREVIATIONS 
bp – Base Pairs 
 
cM – centimorgan; 1,000,000 base pairs 
 
CIP - Calf Intestinal Phosphatase 
 
DS – Double Stranded 
 
ECG – Electrocardiogram 
 
ETBR – Ethidium Bromide staining 
 
GPD1L – Glycerol-3-Phosphate Dehydrogenase 1-Like 
 
HGH – Human Growth Hormone 
 
ICD - Implantable Cardioverter Defibrillator 
 
MCS – Multiple Cloning Site 
 
MHC – Myosin Heavy Chain Promoter 
 
MUT – pBluescriptGPD1L _A280V Mutant 
 
MUT1 – pBK-CMVGPD1L_A280V mutant 
 
MUT2 - α-MHCpBluescript II SK+GPD1L_A280V mutant 
 
PCR – Polymerase Chain Reaction 
 
RE – Restriction Endonuclease 
 
SCD – Sudden Cardiac Death 
 
SCN5A – Sodium Channel Na1.5; Alpha Subunit 
 
 xi 
SS – Single Stranded 
 
in-vivo - living system 
 
WT – pBluescriptGPD1L _A280A wildtype 
 
WT1 – pBK-CMVGPD1L_A280A wildtype 
 
WT2 - α-MHCpBluescript II SK+GPD1L_A280A wildtype 
 xii 
PREFACE 
 
A special thanks to Dr. Barry London, PhD; MD Chief of Cardiology and Director of CVI at 
UPMC for the opportunity to perform this project in his laboratory. I would also like to thank 
Kenny Rahl, BS for his help in performing the Southern Blot analysis for this study. Lastly I 
would like to thank and acknowledge the involvement of the University of Pittsburgh Transgenic 
Facility for their participation in producing the transgenic mice. 
 
 
 xiii 
1.0  INTRODUCTION 
The Brugada syndrome is a rare familial autosomal dominant cardiovascular disorder with 
variable phenotypic expression (1, 4, and 12). In 1992 it was first clinically described as a 
syndrome of recurrent arrhythmias and sudden cardiac death (SCD). The Brugada Syndrome is 
associated with apparent cardiac right bungle branch block and ST segment elevation in the 
precordial electrocardiogram (ECG) leads V1-V3 (4). About 20-50% of patients have a family 
history of SCD (4, 12). In Southeast Asia the Brugada syndrome is the most common cause of 
SCD in young adults with otherwise normal hearts (7). The disease is more prevalent in men 
than in women (1). Currently the only effective treatment for the Brugada syndrome is an 
implantable Cardioverter Defibrillator (ICD) (5, 6), although the effectiveness of this treatment is 
controversial (8). In the past, many drug therapies have been used with no long term efficiency in 
preventing SCD and some are unfortunately related to an acquired form of the Brugada 
syndrome (9, 13). With the occurrence of sudden cardiac death being the only apparent presence 
of the syndrome in many patients, there is need for more research on the detection and 
prevention of the Brugada Syndrome. 
The search for better medical interventions for the Brugada syndrome can begin with the 
identification of causative and deleterious genetic mutations. Until now the only genetic cause of 
Brugada syndrome has been linked to more than eighty reported mutations in the gene SCN5A. 
This gene encodes the α-subunit of the cardiac sodium channel (1, 2, 3, 12, and 14). However, 
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mutations in the SCN5A gene account for only 20% of current Brugada syndrome cases (9). In 
2002 a new gene locus was mapped to a 0.9 cM region on chromosome 3p24 (LOD score > 4) in 
a large multigeneration family (16). It was classified as a distinct autosomal dominant form of 
the Brugada syndrome that is age and sex dependent (16). Through direct sequencing of selected 
candidate genes located in the 3p24 region, a mutation in the glycerol-3-phosphate 
dehydrogenase 1-like (GPD1L) gene was identified. The mutation is a single base change (C/T) 
that creates an amino acid substitution of alanine to valine in a conserved amino acid (A280V) in 
exon 6 of the gene. GPD1L is the second described gene that mutations lead to the Brugada 
syndrome. 
Preliminary cell physiological studies using whole cell patch clamp technique, show a 
61.4% reduction in peak sodium current in cells expressing the mutant GPD1L gene versus cells 
expressing the wild type gene. Northern blot analysis showed tissue-specific RNA expression of 
GPD1L in human tissues with the highest gene expression in heart tissue as seen in Figure 1 
below. However, the function of the GPD1L protein still remains unknown. Exploration and 
understanding the cellular function and molecular interaction of GPD1L with the SCN5A gene 
will require a direct in vivo approach. The creation of transgenic models will provide an animal 
model for understanding the genetic basis of GPD1L mutation in the Brugada syndrome. This 
thesis describes the design and creation of two transgenic mouse lines specifically for GPD1L 
over expression studies. These transgenic mice will enhance current research capabilities and aid 
in finding new avenues for the effective treatment of the Brugada syndrome.   
Transgenic mice are commonly used as in-vivo models to study Human diseases 
(10, 11, 15, and 16). Since the early 1980’s, transgenic models engineered with the various 
molecular genetic techniques can produce an ideal study model with incomparable molecular and 
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cellular research capabilities (10, 11, 15, and 16). Currently there is no mouse model for the 
study of the Brugada syndrome. Therefore the introduction of a transgenic Brugada Syndrome 
mouse will provide an essential in vivo model system to better understand the role of GPD1L 
mutations in the Brugada syndrome and to characterize its function in modulating the cardiac 
sodium channel. 
 
 
 
 
 
 
Figure 1 Tissue specific expression of GPD1L gene.   
Northern Blot analysis GPD1L gene expression in Human tissues was performed using a pre-hybridized blot 
from Clontech and a 32P-dCTP labeled cDNA probe of 346 base pairs in length. The probe aligned to the 3’ 
end of the Human GPD1L mRNA sequence between nucleotide 955 to 1299. The lanes of the blot are labeled 
1-10 and are as follows; 1 Markers, 2 blank, 3 Brain, 4 Placenta, 5 Skeletal muscle, 6 Heart, 7 Kidney, 8 
Liver, 9 Spleen and 10 Colon. 
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2.0  BACKGROUND 
2.1 TRANSGENIC MOUSE MODELS 
A transgenic mouse is a genetically engineered mouse that contains foreign DNA in one or many 
of its cell types (18). The foreign DNA is usually in the form of a DNA construct produced by 
molecular cloning techniques. Molecular cloning in this study produced a wild type and mutant 
GPD1L construct. The construct is then used to express the gene of interest by randomly 
inserting it into the mouse genome using a method known as pronuclear injection. This method 
works by first injecting the recombinant DNA, or transgene as it is now called, into the 
pronucleus of a sperm head located within a fertilized egg (10, 11, and 16). The transgene can 
randomly integrate anywhere within the genome and do it multiple times (18). The pronuclei of 
the egg fuse to form a diploid zygote. The zygote divides to form a mouse embryo. The 
developing embryos are injected into a surrogate mother where they mature and produce 
genetically altered mice containing the specific transgene. The pronuclear injection method has 
been the most commonly used method for transgenic model production since the early 1980’s 
(10). One reason for the popularity of the pronuclear injection method is that it can be used to 
characterize a specific promoter and its ability to direct tissue-specific gene expression. Usually 
this is done to test the efficiency or specificity of a promoter by detecting the presence of a 
transgenic reporter gene. Another use is to study the effects of over expressing the host 
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endogenous gene. Comparative DNA genotyping using polymorphisms found in related genes 
can be used with over expressed mice to find molecular mechanisms of possible pathways that 
may be too subtle given the normal expression levels of the gene (18). Or reveal allelic 
interaction crucial for organ or tissue specific function. The novel GPD1L gene plays an 
important pathological role in the Brugada syndrome and with over expression models there will 
be a powerful tool to understand what that role is. 
The success rate for the pronuclear injection method can vary greatly. Many studies have 
shown that only a small fraction, perhaps only one in ten of transgenic lines produced actually 
expresses the transgene that has randomly inserted into their genome. Recently a new technique 
invented to improve the pronuclear injection method seems to be more reliable and greatly 
increases the number of successful transgenic lines by doubling the pronuclei injected into each 
zygote (11). The technique works by injecting three gene specific recombinants into both the 
male and the female pronuclei of the egg instead on just one. There was an estimated 60% 
increase in the yield of viable transgenic lines. This could prove to be very advantageous to 
researchers in the future. 
There are other factors that affect how a transgene can insert into the host genome and 
not be genetically expressed. The estimated numbers of produced transgenic lines showing 
transgene expression depends greatly on the phenotype and the lethality of the transgene at the 
prenatal level (10, 17, and 18). Also the integration site of the transgene can disrupt the 
chromosomal DNA structure of the host genome and introduce insertion mutations that affect the 
vivacity of the transgenic mouse line (16). However, there are a few investigators who have used 
these mutations as molecular markers for characterizing mutant mouse lines. The insertions in 
this case are recessive and in no way harmful to the host (16). 
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2.2 MOLECULAR CLONING 
Cloning is a molecular technique that involves three main components. The first component is 
the fragment of targeted DNA. This can be as small as a synthesized oligo- nucleotide of a few 
base pairs or as large as an entire gene containing several kilobases. The main goal of cloning 
will be to make many copies of this DNA fragment for study. The second component is the 
vector. Common vectors used for cloning are plasmids, cosmids and viruses. The purpose of the 
vector is to act as a carrier molecule that will protect the DNA fragment and enter the host cell to 
create many copies of the inserted DNA. Vectors are unique because they allow selective 
cloning. Most vectors are chosen for selective advantages such as antibiotic resistance, blue and 
white colony screening because of the presence of the Lac-Z gene, lethality to host cells because 
they contain a lethal gene and they can contain a radioactive or fluorescent marker. In the 
cloning process the DNA fragment is inserted into the vector with the use of endonucleases 
called Restriction Enzymes (RE). Restriction enzymes recognize specific DNA sequences and 
cleave the DNA at these sequences. DNA fragments that are cleaved and inserted into a vector 
are called recombinant DNAs. There are many types of restriction enzymes but the most 
commonly used are Type 1 or Type 2. Type 2 enzymes are used more often because they are 
site- specific endonucleases that cut directly at or very close to the recognition site. Type 1 
enzymes usually cut far from the recognition site and are not as useful for cloning. The 
restriction enzymes create a double-stranded (DS) break that can be blunt ended or contain a 
single-stranded single-stranded (SS) overhang of a few bases. Complementary overhanging 
strands are ligated to one another to create a recombinant fragment of DNA. Likewise two blunt 
ended pieces can also be joined to form a recombinant fragment of DNA. Circular DNA 
molecules like plasmids and viruses can be linearized with a single enzymatic digest. 
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The third component is the host cell. The host cells used in molecular cloning are mostly 
bacterial cells like Escherichia coli, Bacillus and streptococcus. Some eukaryotic cells like yeast 
cells are often used. Mammalian cells like HEK cells are used but more for metabolic and other 
biochemical methodology. Host cells used for molecular cloning are called competent cells. 
Competent cells are cells conditioned to accept foreign DNA through cell surface pores hundreds 
of times greater when exposed to environmental changes like heat or electrical shock. In the 
presence of heat the cellular pores are forced open and the plasmid DNA is free to move into the 
host cell in a process called transformation.  After transformation, through the selective 
advantage, only bacteria containing transformed plasmid will be able to grow under the specific 
selective growth condition. Plasmid DNA will be replicated in the cells at an exponential rate. 
Characterization of the plasmid will determine the presence of the cloned DNA fragment. The 
flow charts below illustrate the molecular cloning process in figure 2 and the production of the 
transgenic constructs in figure 3. 
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 Figure 2 Diagram of Molecular cloning. 
A fragment of foreign DNA is ligated to a linearized vector. In this case the vector is a plasmid. Restriction 
enzymes are used to create the compatible ends for ligation. The plasmid/foreign DNA are incorporated into a 
host cell (perhaps E. coli) through a process known as  transformation. The transformed cells are grown and 
plated. The selective properties of the plasmid (antibiotic resistance, i.e.) allow only the cells that contain the 
plasmid/foreign DNA to grow. The colonies are picked and the clone is harvested. 
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Figure 3 Transgenic construct flow chart summarizing the cloning process. 
The mutant clone is produced by mutagenesis of the wild type clone. The initial construct is produced with an 
EcoRI and BamHI digest of the GPD1L clone and the pBK-CMV vector. The final construct is produced with 
a Bsm I/Xho I/ BstUI digest of the pBK-CMV/GPD1L clone and a HindIII/Sal I digest of the α- 
MHCpBluescript II SK+ plasmid. The final mutant clone is produced by mutagenesis of the wild type final 
clone. 
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3.0  MATERIAL AND METHODS 
3.1 PLASMID VECTORS 
1. The GPD1L cDNA clone (~6900 bp) was purchased from Invitrogen (ID# 4820730, cat# 
FL1002). The clone was created by inserting the GPD1L cDNA transcript (3900 bp) into the 
EcoRI and BamHI restriction site located in the multiple cloning site (MCS) of the pBluescriptR 
plasmid (2998 bp) (Stratagene cat# 212206). This construct was referred to as 
pBluescriptGPD1L _A280A wildtype (WT). A plasmid stock solution was made. The antibiotic 
used for clone selection was Ampicillin.  
2. The pBK-CMV plasmid (4518 bp) (Stratagene cat# 212207). A working stock of the pBK-
CMV vector was made. The antibiotic used for clone selection of the pBK-CMV was Kanamycin 
(MPBiomedical cat# 194531). 
3. The α-MHCpBluescript II SK+ plasmid (9.6 kb) below in figure 4. This vector was 
constructed by inserting the α-Myosin Heavy Chain (MHC) promoter (~5000 bp) and the 
polyadenylation (poly-A) signal of the Human Growth Hormone (HGH) (~ 600 bp) into the 
pBluescript II SK+ plasmid (~ 4000 bp).A working stock of the α-MHCpBluescript II SK+ 
plasmid was made. The antibiotic used for colony selection for this plasmid was Ampicillin. 
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Alpha-MHCpBluescript II SK+
MHC -3 exons
MCSSal I
HindIII
Hgh-polyA
pBluescript II SK+
MHC promoter
UTR
~ 9600 bp
pBluescript II SK+
MHC promoter
Poly A tail
 
Figure 4 α- MHCpBluescript II SK+ plasmid. 
3.2 PREPARATION OF BACTERIAL CULTURE MEDIA AND PLATES 
Materials 
1 µl   plasmid 
40 µl chemically competent XL Blue cells (Stratagene cat# 200249) 
500 µl SOC Medium (Invitrogen cat# 15544-034) 
 
 
LB/Antibiotic Broth  
Amplicillin (50 ug/ml) (Fisher cat# BP1760-25).    
Kanamycin (50 ug/ml) (MPBiomedical cat# 194531). 
10g Tryptone (Becton-Dickerson cat# 211705) 
10g NaCl (VWR cat# VW6430-5) 
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5g   Dried yeast extract (Becton-Dickerson cat# 212750) 
1L   dH 0 2
Autoclave for 20 minutes to sterilize. 
Add Antibiotic when broth cools to 50-55oC. 
Store at 4oC. 
 
LB/Antibiotic Plates 
10g Tryptone 
10g NaCl 
5g   Dried yeast 
15g Agar (Becton-Dickerson cat# 214010) 
1L   dH 0 2
Autoclave for 20 minutes to sterilize. 
Set out plates. Add Antibiotic when broth cools to 50-55oC. 
Pipette 25 ml of LB/Antibiotic to each plate.  
Cool at RT until solidified. Store at 4oC. 
3.3 TRANSFORMATION OF CHEMICALLY-COMPETENT CELLS AND 
ISOLATION OF PLASMID DNA 
The chemically-competent XL Blue cells were purchased from stratagene and stored at -80oc.  
At the time of transformation, a vial of the competent cells was removed from the -80oc freezer 
and thawed on ice for 5 minutes. The Plasmid DNA (with or without insert) was removed from 
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the -20oc freezer and also placed on ice to thaw. A 40 µl aliquot of the chemically-competent XL 
Blue cells was transferred to a sterile, labeled 1.5 ml tube for transformation. One micro liter of 
the Plasmid DNA was transferred to the tube containing the 40 µl of competent cells and gently 
mixed. The transformation mixture was incubated on the ice on the ice for 10 minutes followed 
by 50 seconds incubation in a 50 oC dry heat block. During this period the competent cells were 
heat shocked and their pores opened to accept the plasmid DNA. After the 50 seconds were up 
the tube was immediately placed on ice for 2 minutes. During this phase of the transformation 
the cells were cold shocked and their pores were forced close trapping the clone within the cell. 
Then 500 µl of SOC medium (Invitrogen cat# 15544-034) was added to the mixture and 
the tube was placed in a shaker set at 37oC and 250 rpm to incubate for one hour. During this 
time the traumatized cells can revive in a rich nutrient media and be ready for plating after one 
hour. During this time two LB/ Antibiotic plates were placed in a 37oC incubator to warm before 
plating. After the incubation the cells were removed from the shaker and the two LB/Antibiotic 
plates retrieved from the incubator. A 1:10 dilution of the cells using sterile dH2O was 
performed and 1 µl of the dilution was transferred and spread to one plate and 1 µl of the 
undiluted cells was transferred and spread on the other plate. The plates were covered and 
inverted for placement back into the incubator for at least 18 hours. 
The plates were removed from the incubator. Then 250 ml of room temperature 
LB/Antibiotic broth was added to a sterile 500 ml flask. One colony from the plate was used to 
inoculate the LB media. The flask was covered with parafilm to avoid splash out. The flask was 
then placed in a 37oC shaker at 250 rpm for 18 hours. The flask was removed the next day and 
the cultured media was transferred to a centrifuge bottle. The broth was centrifuged at 6000 rpm 
at 4oC for 30 minutes. The bottle was removed from the centrifuge and the supernatant was 
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discarded. Then the pellet was processed for plasmid purification using the Qiagen Maxi-plasmid 
prep kit (cat# 12162) and following the Maxi prep protocol in the Qiagen Plasmid Purification 
Handbook. The purified plasmid was resuspended in 1 ml of 1x TE. A small aliquot of the 
resuspension was placed in a spectrophotometer to measure concentration as well as purity of the 
DNA stock. 
3.4 AUTOMATED DNA SEQUENCING 
BigDye Terminator Sequencing was used to verify that the insert was intact. Sequencing 
reactions were performed using the primers in Table 1 below. These primers sets were designed 
to overlap each other and span the entire cDNA region of the GPD1L gene. 
 
Table 1 GPD1L Primers used for DNA sequencing. 
Name Primer Sequence 5’ to 3’ 
1F CCGGCCAGGGAAGCACG 
1R ATGAGTCCCAGGCGGATGACG 
2F CTTAAGAACATCGTAGCTG 
2R GTAAAAATTCATACATATCCG 
3F TGATCAATCTTTTGGGTTCAC 
3R CCTCTGAGCCTTGACGAA 
4F TCCCCCTCACTGCAGTTGTC 
4R TTGACCTTTCCAGGGAACACC 
5F GTCCCAAGAGCCAGTGATTAT 
5R TGAGACAAGCAAAGTGGGTTA 
6F CACAGAAGTATACGAAAGCAC 
6R TGAGCTGCTAATCTAGGTGT 
7F CTGTGGTCCATTGTTCAT 
7R ATGTATGTAAAAGGCTAGCAG 
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 Set up the Bigdye reaction. 
 
50-100 ng Plasmid DNA 
1 µl   1µm primer (forward or reverse) 
3 µl   Bigdye reaction mix v.1.1 (Applied Biosystems cat# 4337455) 
X-10 µl   dH 0 2
10 µl 
 
 
Amplify in the ABI Thermocycler 9700 
 
25 cycles 
95oC     5 seconds 
50 oC   10 seconds  
60 oC   4 minutes 
 
4 oC      forever 
 
Remove the tubes from the 9700 and place them in a 96 well PCR tube plate. The following 
protocol was used to remove residual bigdye terminator prior to the sequence analysis. Transfer 
10µl of dH 0, 2 µl 2M NaAO2 c, and 50 µl of 100% ethanol to the each reaction tube. Recap the 
tubes and invert the plate three times. Place the plate in a centrifuge and spin at 2000 rpm at RT 
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for 30 minutes. Remove the tubes from the centrifuge and uncap them. Invert the tube plate on a 
folded paper towel to remove almost all of the supernatant by gently shaking once. Then transfer 
150 µl of 70% ethanol to the tubes. Recap the tubes and place the plate back in the centrifuge for 
10 minutes. Remove the plate and uncap the tubes. Invert the plate onto a folded paper towel and 
placed back in the centrifuge in the inverted position with the paper towel. Centrifuge at 700 rpm 
for 1 minute. Remove the plate and discard the paper towel. To the dry tubes add 30 µl of 
Deionized Di-formamide. 
Transfer the 30 µl of Deionized Di-formamide (Applied Biosystems cat# 4311320) in 
each tube to an ABI 310 sample vial (Applied Biosystems cat# 401957). Place a rubber septa 
(Applied Biosystems cat# 401956) on the vial. Denature the sample at 95oC for 2 minutes. Place 
on the ABI 310 for sequencing and analyzed using sequencing analysis and blast 
(http//www.ncbi.nim.nih). 
3.5 MUTAGENESIS 
The A280V form of the GPD1L was produced with mutagenesis by the incorporation of the C/T 
base change into the WT clone. Primers were designed for priming the polymerase chain 
reaction on the sense and anti-sense strands of the plasmid. These primers are sense; 
5’GGTGGCCGAGGCCTTCGTCAGAACTGGGAAGACC-3’ and anti-sense; 5’-
GGTCTTCCCAGTTCTGACGAAGGCCTCGGCCACC-3’. Mutagenesis was performed using 
the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene cat# 200514).  
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Set up the PCR
100 ng   Plasmid DNA 
1 µl             20 µm sense primer (IDT Technologies) 
1 µl             20 µm antisense primer (IDT Technologies) 
5 µl            10X  Reaction Buffer 
1 µl            10 mM dNTPs 
1 µl          QuikChange Multi enzyme blend 
x to50µl                   dH 0 2
50 µl  
 
Amplified in the ABI 9700 using the following PCR parameters: 
 
 
1 cycle 
  95oC          1 minutes 
30 cycles                        
95oC           1 minute 
55oC           1 minute 
65oC           8-12 minutes (2 minutes for every 1 kb of plasmid length) 
1 cycle 
4oC             forever 
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The PCR products were digested with Dpn I by transfer of 1µl Dpn I RE (NEB cat# 
R0176S) to the PCR products at 37oC for 1 hour. The Dpn I will selectively degrade the 
methylated original WT PCR template and leave only PCR products containing the site-specific 
mutations. 
A two to four microliter aliquot of the digestion mixture was directly used to 
transform the XL Blue cells as described above for the wild type plasmid except for the following 
changes. Three plates were used to plate 25µl, 50µl and 100µl volumes. The plates were covered 
and inverted for placement back into the incubator for a minimum of 18 hours. Then 20 colonies 
from mutant plates were picked and placed in 20 sterile labeled 15 ml tubes containing 10 ml of 
room temperature LB/Antibiotic broth. These tubes were placed in a 37oC shaker at 250 rpm 
overnight. The next day the tubes were processed using the Qiagen Mini-plasmid prep kit (cat# 
27106) and following the mini prep protocol in the Qiaprep Miniprep Handbook. The 20 clones 
were then analyzed by direct sequencing of the insert to make sure inserted mutation is present 
and intact using Bigdye terminator as follows. A stock concentration is carried out as above and 
the mutant clone was ready for use. The mutant clone was referred to as A280V Mutant (MUT).  
3.6 RESTRICTION ENZYME DIGESTS 
The restriction enzymes and reaction conditions used in this study are summarized in Table 2 
below. 
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Table 2 Conditions for Restriction Enzyme digests. 
oRE NEB Cat# Buffer # BSA Temp C  
EcoRI R0101S EcoRI Yes 37 
BamHI R0136S used EcoRI Yes 37 
Bsm I R0134S 2 No 65 
HindIII R0104S 2 No 37 
Sal I R0138S 3 Yes 37 
Xho I R0146S 2 No 37 
Bst UI R0518S 2 No 60 
Not I R0189S 2 Yes 37 
Kpn I R0142S 1 Yes 37 
Sac I R0156S 1 Yes 37 
Cla I R0197S 4 Yes 37 
Bovine Serum Albumin (BSA) - 10 mg/ml. (NEB cat# B9001S) 
 
The following reactions were used for restriction digestion. Digestions with both a single 
enzyme and two enzymes simultaneously (double digest) are shown. 
Reaction setup 
 
Single Digests 
Plasmid DNA                                    10 µl 
Restriction Enzyme                              2 µl 
10x  BUFFER                                       5 µl 
 BSA (if needed)                                0.5 µl 
dH2O                                               32.5 µl 
                                                        50.0 µl 
 
Double Digests 
Plasmid DNA                                    10 µl 
Restriction Enzyme                           1.5 µl 
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Restriction Enzyme                           1.5 µl 
10x  BUFFER                                       5 µl 
 BSA (if needed)                                0.5 µl 
dH2O                                               31.5 µl 
                                                        50.0 µl 
 
 
The reactions were set up in a sterile labeled 0.5 ml tube. The tubes were capped and 
covered with parafilm to reduce evaporation. The reactions were then incubated overnight in a 
(enzyme specific temperature) heat block. The next day the restriction products were examined 
by electrophoreses on a 1% agarose gel (Low EOE/BioExpress E-3120-500) Agarose containing 
Ethidium Bromide(ETBR) (Fisher cat# BP102-1)) staining. A Lambda BstE-digest ladder (New 
England Biolabs cat# N3014S)) was used for molecular weight standard. The products were gel 
extracted using the Qiagen Gel extraction kit (cat# 28704) and following the Qiaquick protocol 
in the Qiaquick Spin Handbook pp.23-24. The products were then used for the ligation reaction 
below. 
 
 
 
 20 
3.7 LIGATION AND TRANSFORMATION OF GPD1L INSERT AND PLASMID 
DIGESTED PRODUCTS: 
 
A typical ligation reaction was set up as the following: 
 
5 µl        GPD1L (WT) insert  
1 µl        plasmid  
1 µl        10x T4 Ligation Buffer 
2 µl        dH2O 
1 µl        T4 Ligase (NEB cat# M0202S) 
10 µl        
 
The ligation reaction was set up in a sterile labeled 0.5 ml tube. The tube was capped and 
covered with parafilm to reduce evaporation. Then placed in a 16oC water bath and incubated 
overnight. The next day the ligation was transformed with chemically competent XL Blue cells 
as before. During the incubation of the cells in 500 µl of SOC media for 1 hour; three 
LB/Antibiotic plates for both WT and MUT transformants were placed in the incubator for pre-
warming. The cells were plated as follows: 
 
Plate 1_25 µl of transformation mixture 
Plate 2_50 µl of transformation mixture 
Plate 3_100 µl of transformation mixture 
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 The plates were covered and inverted for placement back into the incubator for 18 hours. Then 
20 colonies from the WT plates and the MUT plates were picked and placed in labeled sterile 15 
ml tubes containing 10 ml of room temperature LB/Antibiotic broth. These tubes were incubated 
in a 37oC shaker at 250 rpm overnight. The next day the tubes were processed using the Qiagen 
plasma purification kit as above. The 20 colonies from both wild type and Mutant were verified 
by direct sequencing of the insert to make sure GPD1L transcript was intact using bigdye 
terminator primers from Table 1. 
3.8 PHENOL/CHLOROFORM EXTRACTION 
To 1.5 ml tubes containing the plasmid DNA add 50/50 phenol chloroform solution to two times 
the DNA suspension volume. Then in a microcentrifuge spin the mixture 14,000 rpm for 2 
minutes. Transfer only the top layer of the mixture to a new 1.5 ml tube and add 100% 
chloroform to two times the extracted volume in the tube. Discard the bottom layer of phenol 
remaining in the tube to the proper waste jar. Centrifuge for this time for 15 minutes at 14000 
rpm. Remove the tube from the centrifuge and discard any phenol left at the bottom of the tube. 
Next proceed to Ethanol/Acetate precipitation of DNA. 
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3.9 ETHANOL PRECIPITATION 
To the DNA suspension add 1/10 the volume of 7.5 M NH AO4 c and 3 µl 100 mg/ml Glycogen 
(Invitrogen cat# 10814-010). Then add 900 µl cold 100 % ethanol and place the mixture in a -
80oC freezer for 15-30 minutes. Remove the mixture tube from the freezer and place in a 
microcentrifuge to spin at 14,000 rpm at a temperature of 4oC for 30 minutes. Remove the tube 
from the centrifuge and discard the supernatant carefully to avoid disturbing the DNA pellet. 
Next add 500µl of 70% ethanol and place the tube back in a microcentrifuge at 14,000 rpm at 
4oC for 10 minutes. Remove the tube and again discard supernatant carefully. Invert the tube on 
a paper towel to dry the pellet for five to ten minutes. Then store the tube containing the dry 
pellet in a -20oC freezer or resuspend it in 1x TE buffer.  After the clean-up the linearized α-
MHCpBluescript II SK+ plasmid and the GPD1L fragments were blunt ended with the Klenow 
fragment. 
3.10 KLENOW REACTION  
Klenow reaction of DNA fragments was conducted according to the protocol described by the 
manufacturer (New England Biolabs, NEB cat# M0212S). Briefly, add 5 µl of reaction buffer, 
1µl of 10 mM dNTPs and 1µl of Klenow fragment to a tube containing the plasmid DNA. Bring 
the total reaction volume to 50 µl with sterile dH20 and incubate for 30 minutes in a 37oC heat 
block. Remove the tube and cleanup the DNA using the phenol/chloroform and ethanol 
precipitation protocols mentioned above. 
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3.11 CIP (CALF INTESTINAL/ ALKALINE PHOSPHATASE) REACTION  
The CIP reaction was conducted according to the protocol described by the manufacturer (New 
England Biolabs, NEB cat# M0290S). Briefly, add 5 µl of reaction buffer, 0.5µl of 10 mg/ml 
BSA and 1µl of Calf Intestinal/ Alkaline Phosphatase to a tube containing the plasmid DNA. 
Bring the total reaction volume to 50 µl with sterile dH20 and incubate for 60 minutes in a 37oC 
heat block. Remove the tube and cleanup the DNA using the phenol/chloroform and ethanol 
precipitation protocols mentioned above. 
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4.0 RESULTS
4.1 CONSTRUCTION OF THE pBLUESCRIPTR/GPD1L CLONE 
The initial vector containing the entire cDNA of human GPD1L was purchased pre-constructed 
from Invitrogen and was constructed as follows in figure 5. This plasmid was used as the initial 
wild type clone of the GPD1L gene. 
pBluescriptR
BamHI
GPD1L cDNA
~3980bp
Ligation
TRANSFORMATION
pBluescript/GPD1L
clone
GPD1L
5’ 3’
5’
3’
pBluescript/GPD1L clone
Figure 5 Construction of pBluescriptR/GPD1L clone. 
The GPD1L cDNA transcript (~3980 bp) was inserted into the pBluescriptR plasmid (~2900 bp) utilizing the
 BamHI cut site of the plasmid multiple cloning sites. The produced clone is ~ 6900 bp in length. 
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4.2 MUTAGENESIS OF pBLUESCRIPT/GPD1L WILD TYPE CLONE 
The pBluescript/GPD1L wild type clone was used to create the A280V mutant with a technique 
known as site directed mutatgenesis. Site directed mutagenesis of the pBluescriptR/GPD1L wild 
type clone (6900 bp) was performed by using both a sense strand and an anti-sense strand oligo 
to incorporate the A280V mutation into the GPD1L transcript during a polymerase chain 
reaction (PCR).  The two specific oligos ensured that the PCR would produce two 
complementary strands, each containing the A280V mutation, and eventually a double-stranded 
mutant homozygote as the final result. The wild type DNA was then removed from the reaction 
tube with the Dpn I enzyme. The Dpn I endonuclease recognizes dam methylated DNA and 
digests the DNA sequences at these sites. The wild type clone contained the dam methylated 
sites when it was originally isolated using a bacteria host. A bacterial cell uses dam methylation 
as a way to protect its genomic DNA from degradation by restriction enzymes. Methylation 
occurs on the adenine of every GATC string in the DNA transcript of the clone and the Dpn I cut 
at these sites. The remaining mutant products were transformed and the mutant clone was 
produced.  Below in figure 6 is an illustration of site-directed mutagenesis process and in figure 
7 are the DNA sequences of the wild type and mutant clones showing the homozygous C to T 
base change. 
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pBluescriptR
GPD1L
GPD1L Sense
GPD1L Anti-sense
A280V
A280V
5’ 3’
3’ 5’
DPN 1
Digest
Transformation
pBluescriptR
GPD1L
Mutant
A280V
PCR
Anti-sense Oligo
Sense Oligo AAAAA
AAAAA
(Remove WT)
 
Figure 6 Site-directed mutagenesis of the pBluescriptR/GPD1L wild type clone. 
The selected clone was verified by DNA sequencing. Below is a comparison of the wild type and mutant clone. 
 
A.      B. 
 
Figure 7 Sequence comparison of wild type and mutant GPD1L. 
A. The red arrow shows the wild type Alanine amino acid (GCC). B. The red arrow shows the mutant 
valine residue (GTC) after mutagenesis. 
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4.3 CREATION OF pBK-CMV/GPD1L INTERMEDIATE CLONE 
The wild type and mutant GPD1L clones were then inserted into the pBK-CMV vector to create 
the intermediate construct. The pBluescript/GPD1L clones and the pBK-CMV vector were 
digested with restriction enzymes EcoR1 and BamHI. Both enzymes produce four base single 
strand overhangs also called sticky ends. The complementary sticky ends of the GPD1L clones 
and the pBK-CMV vector were ligated to form the new recombinant. The restriction products 
were examined by electrophoreses on a 1% agarose gel (Low EOE/BioExpress E-3120-500) 
Agarose containing ETBR (Fisher cat# BP102-1)) staining. A Lambda BstE-digest ladder (New 
England Biolabs cat# N3014S)) was used for molecular weight standard. The 
pBluescript/GPD1L digests produced two bands. The GPD1L cDNA band was approximately 
3627 base pairs (bp) and the linearized pBluescript plasmid band was around 3273 bp. The 3627 
bp GPD1L band was excised and the pBluescript band was discarded. Below in figure 8 is an 
illustration of the cloning process and in figure 9 is a gel picture of the pBluescriptR (pBsR) 
plasmid and GPD1L clone with the digestion. 
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BluescriptR
GPD1L
pBK-CMV
GPD1L
Ligation
EcoRI
BamHI
pBK-CMV
EcoR
I
B
am
H
I
Kpn I
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Figure 8 Construction of pBK-CMV/GPD1L clone (~8127 bp). 
EcoRI and BamHI digestion excised the GPD1L transcript (~3627 bp) from the pBluescript/GPD1L clones 
and allowed insertion into the pBK-CMV vector (4500 bp). The illustration also shows the restriction enzyme 
cut sites used to verify the final clone. 
 
Bst-E
pBsR
pBsR
GPD1L
pBsR
GPD1L
EcoRI
BamHI
digest
Bst-E
6.9kb
3.0kb
6.9kb
3627bp GPD1L
3273bp
 
Figure 9 Gel picture of pBluescriptR/GPD1L clone and EcoRI/BamHI digest. 
The Lanes left to right show Bst-E ladder, linearized pBluescriptR plasmid, Linearized pBluescriptR/GPD1L 
clone, EcoRI/BamHI digest of pBluescriptR/GPD1L clone and Bst-E ladder, respectively. 
 
 29 
The linearized pBK-CMV plasmid and the 3627 bp GPD1L fragment were ligated to form the 
finished GPD1L intermediate construct (8127 bp). To characterize the clones obtained with 
cloning, partial clones were analyzed using restriction enzyme digestion. Below in figure 10 is a 
gel picture showing the pBK-CMV plasmid (4500 bp) and the pBK-CMV/GPD1L clone (8127 
bp) linearized with Sac I digestion. Also pictured is the pBK-CMV/GPD1L linearized with a 
double digest using Kpn I and Sac I restriction enzymes. As expected the excised GPD1L 
fragment (3725 bp) and linearized pBK-CMV plasmid (4402 bp) were visible after the Kpn I/ 
Sac I digests. The fragments were sized with the Bst-E molecular size marker shown. 
Bst-E
pBK-CMV
Linearized
w/Sac I
pBK-CMV/GPD1L
Linearized w/Sac I
pBK-CMV/GPD1L
Double digest
w/ Sac I and Kpn I
Bst-E
8127 bp
4500 bp 4402 bp
3725 bp
 
Figure 10 Restriction analysis of pBK-CMV clone. 
Lanes left to right show Bst-E ladder, Sac I linearized pBK-CMV (4500 bp), Sac I linearized pBK-
CMV/GPD1L (8127 bp), double digest Kpn I/Sac I of pBK-CMV/GPD1L (4402 bp plasmid and 3125 bp 
GPD1L insert and Bst-E ladder, respectively. 
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4.4 Α-MHCpBLUESCRIPT II SK+ /GPD1L CLONE CONSTRUCT 
The α-MHCpBluescript II SK+ plasmid was a vector used to build transgenic constructs for 
generating transgenic mice. The GPD1L intermediate clone, pBK-CMV/GPD1L, was used to 
clone the GPD1L gene into this vector. The cloning process to create the constructs required 
more steps than making the first recombinant. There were three rounds of digests in this process. 
The strategy for doing the cloning this way was to first of all make use of available 
complementary cut sites within the GPD1L and MHC vector, and second was to make sure the 
piece would be ligated into the vector in the right orientation for expression. The MHC promoter 
will initiate transcription of the 5’ end containing the start codon (ATG or Methionine) of the 
GPD1L transcript and therefore needs to precede the 5’ end. The 3’ end containing the GPD1L
stop codon (TAA) must precede the polyadenylation sequence in order for the addition of the 
poly-A tail on the 3’ end of the transcribed message. To achieve the desired orientation with the 
limited cut sites available the process took three rounds of restriction digests. 
4.4.1 First round: 
 13 
The first round of digests was as follows. The Bsm1 RE creates a blunt end cut. This blunt end 
was ligated to the HindIII RE end of the vector. However the HindIII RE left a four base 
overhang and was not compatible with the BsmI blunt end. Therefore an extra step was added to 
blunt the HindIII RE end. This technique was accomplished with the help of an enzyme called 
Klenow. The Klenow fragment is actually a DNA polymerase that can be used to fill in the 
overhang and blunt it. After the Klenow reaction the second digest was performed. 
4.4.2 Second round: 
The second digest created a compatible sticky end (overhang) on the GPD1L cDNA fragment 
and the linearized α-MHCpBluescript II SK+ plasmid. The products were digested to produce the 
sticky ends needed for ligation and orientation into the vector. It was most important to produce 
the sticky ends to ensure that the DNA fragments were ligated in the right orientation. A double 
blunt-ended ligation can orient either way and the resulting clone would be useless if the 
promoter was not preceding the 5’ end of the GPD1L transcript. The restriction sites available 
for the compatible sticky ends were very limited so a special technique was used. Some 
restriction enzymes are unique in that the overhang of one enzyme may be similar enough to the 
overhang of another that they will ligate together. However this kind of ligation usually destroys 
the specificity of the recognition site and it cannot be cut with one or both of the enzymes ever 
again. However, because of the limited sites to use this was the best option available. The two 
enzymes that are most commonly used in this fashion are Sal 1 RE and Xho 1 RE. They both 
create a four base 5’ overhang of AGCT (sticky end) and therefore are compatible in a ligation 
reaction (figure 11). 
Sal 1 recognition site 
 
Xho 1 recognition site 
 
Figure 11 Compatible overhangs for Sal I and Xho I 
Notice that the two recognition sites are very similar. The overhangs produced can be ligated together but the 
site will be altered so that the original recognition site is changed and unrecognizable by one or both of the 
enzymes. 
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After the digest the restriction products were examined by electrophoreses on a 1% agarose gel 
containing ETBR staining. Only a small aliquot of the GPD1L products was examined. A 
Lambda BstE-digest ladder was used for molecular weight standard. The pBK-CMV/GPD1L 
digests produced several bands. The GPD1L band (3423 bp) was too close in size to the plasmid 
band (4260 bp) and did not separate enough on a 1% agarose gel to excise the band with 
certainty. For this reason a third round of digest was performed on the GPD1L products to ensure 
the right product was excised. 
4.4.3 Third round: 
The third round was to digest the plasmid fragments so that the GPD1L fragment was 
distinguishable and could be excised from the gel. The enzyme BstU1 RE was chosen because 
there were many recognition sites in the pBK-CMV plasmid but none in the GPD1L piece. The 
restriction products were examined by electrophoresis on a 1% agarose gel Agarose containing 
ETBR staining. A Lambda BstE-digest ladder was used for molecular weight standard. The 
digest can be seen in the cartoon below in figure 12. After the fragment became distinguishable 
from the plasmid fragment; the entire digested product was run on another agarose gel and the 
GPD1L band (3423 bp) was excised. The product was gel extracted and purified for the ligation 
reaction. 
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pBK-CMV 
GPD1L 
 
Figure 12 Illustration of BSTUI digest. 
The GPD1L transcript (3423 bp) is located between the upper Xho I and lower Bsm I sites as shown by the 
arrows. There are many BstUI recognition sites in the pBK-CMV fragment that help to distinguish the 
GPD1L fragment on a 1% agarose gel. 
 
Below in figure 13 is an illustration of the cloning process and in figure 14 an illustration of the 
final clone. 
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Figure 13 Creation of final construct. 
The pBK-CMV/GPD1L clones were digested with the Bsm I and Xho I restriction enzymes to remove the 
GPD1L transcript. The α-MHCpBluescript II SK plasmid was digested with the HindIII and Sal I restriction 
enzymes to allow the insertion of the GPD1L transcript. The illustration also shows the other restriction 
enzyme cut sites used to verify the final clone. 
 
MHC
Sal I / Xho I
GPDIL insert
HindIII / BSM I
Blunt end 
ligation
Hgh-polyA
Not I
pBluescript II SK+
Not I
Alpha-MHCpBluescript II SK+ / GPDIL
clone
~ 12,500 bp048 
 
Figure 14 α-MHCpBluescript II SK+GPD1L clone. 
The figure shows the final vector with the GPD1L insert. The GPD1L insert is oriented with the 5’ end where 
the Sal 1/Xho I ligated site and the 3’end at the HindIII/BsmI site. The GPD1L construct is now complete 
with a promoter, coding region and poly-A signal.  
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The digested products for the molecular cloning process for making the constructs is shown on a 
1% agarose gel in figure 15 and 16. Figures 17, 18 and 19 show the verification digests for the 
clone. Figure 17 shows the α-MHCpBluescript II SK+ plasmid and α-MHCpBluescript II SK+ 
/GPD1L clone linearized with a single cut of the Cla I restriction enzyme to verify the presence 
of the GPD1L transcript in the clone. Figure 18 shows the Not I digestion of the α-
MHCpBluescript II SK+ /GPD1L clone and in figure 19 an illustration of the final transcript. 
This was the final product sent to the University of Pittsburgh Transgenic Facility. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1716 18
3423 bp
 
Figure 15 Gel showing the creation of WT1 and MUT1. 
Shown also is the extraction from the pBK-CMV plasmid for the final cloning. Lanes 1, 9, 11 and 18 are the 
BSTE ladder for fragment sizes. Lanes 2 and 4 show the WT and MUT clones. Lanes 3 and 5 show the EcoRI 
and BamHI double digest of the two clones. Lane 6 is the pBK-CMV plasmid. Lane 7 is the EcoRI and BamHI 
double digest of the plasmid. Lanes 8 and 10 show the WT1 and MUT1 clones. Lanes 12 and 13 is the Bsm I 
digest of WT1 and MUT1. Lanes 14 and 15 show the Xho I digest. Finally, Lanes 16 and 17 are the third 
round BstUI digested products of WT1 and MUT1. Notice the 3423 bp piece. 
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1 2 3 4 5 6 7 8 9
 
Figure 16  Gel showing the creation of WT2 and MUT2. 
Lanes 1 and 9 are the BSTE ladder. Lane 2 is the uncut α-MHCpBluescript II SK+ plasmid. Lanes 3 and 4 
show the HindIII and Sal I digested α-MHCpBluescript II SK+ plasmid, respectively. Lanes 5 and 6 are the 
WT2 and MUT2  clones. Lanes7 and 8 show the final Not I digest of WT2 and MUT2. 
 
12048 bp
9600 bp
α-MHCpBluescript II SK plasmid α-MHCpBluescript II SK+GPD1L
 
Figure 17 Gel picture showing Cla I linearized α-MHCpBluescript II SK+ plasmid 
and α-MHCpBluescript II SK+ /GPD1L to verify presence of GPD1L transcript in clone. 
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Bst_E Ladder
~ 9023 bp
~ 3025 bp
 
Figure 18 Not I digestion 
producing final transcript sent to mouse facility. The 9023 bp fragment is the final transcript containing the 
MHC promoter, GPD1L transcript and the HGH poly-A signal sequence. 
 
Wildtype Construct
Mutant Construct
MHC Promoter
MHC Promoter
GPD1L
GPD1L
HGH plA
HGH plA
Not INot I
Not I Not I
 
Figure 19 Final construct after Not 1 RE digest. 
The figure shows the final constructs contain a promoter, the GPD1L transcript and the HGH 
polyadenylation signal sequence with the two Not I restriction site locations. The mutant is also labeled with 
an arrow showing that the A280V mutation is present. 
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The final transformation produced a wild type clone but not a mutant. There is the possibility 
that the mutant GPD1L fragment was altered during the three rounds of digests and the resulting 
5’ and 3’ ends were made incompatible with the corresponding plasmid ends. During a 
restriction digests the sequence of the 5’ or 3’end of a DNA fragment can be altered slightly 
leaving it incompatible for ligation. The three digests were performed on the intermediate mutant 
clone again. The ligation reaction was set up and no colonies were produced after transformation 
a second time. Finally after one more attempt to produce the mutant, mutagenesis was performed 
on the wild type clone to produce a valid mutant clone. The same protocol was used as in the 
production of the pBluescriptR/GPD1L mutant shown above in B and shown in figure 20 below. 
α-MHCBluescriptSK
GPD1L
Wild type
GPD1L Sense
GPD1L Anti-sense
A280V
A280V
5’ 3’
3’ 5’
DPN 1
Digest
Transformation
α-MHCBluescriptSK
GPD1L
Mutant
A280V
PCR
Anti-sense Oligo
Sense Oligo AAAAA
AAAAA
(Remove WT)
 
Figure 20 Mutagenesis of α-MHCpBluescript II SK+ /GPD1L wild type clone. 
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4.5 PRONUCLEAR INJECTION 
The wild type and mutant clones of GPD1L were used for pronuclear injection to generate 
transgenic mice. The first two litters were obtained two months after injection.  Mouse tails were 
obtained from these litters and tail DNA was extracted from 24 offspring produced from the wild 
type GPD1L transgene injection and 14 tails from the mutant GPD1L injection. Kenny Rahl, a 
molecular technician in the lab, performed a southern blot on the DNA. Southern blotting is a 
method using radio-isotope labeled probes to detect the presence of a specific DNA sequences or 
a transgene. Two probes were designed to test for the presence of the transgene. One probe was 
homologous to the MHC promoter and the other probe was homologous to the human GPD1L 
transcript. The probe for the MHC promoter should hybridize to the native mouse MHC 
transcript as well as the transgenic copy producing two bands on the blot. The GPD1L probe was 
homologous to the human GPD1L and one band should be seen only if the transgene is present 
in the mouse genome. Unfortunately, the southern blot showed that the transgenic MHC and the 
GPD1L transgene were not present. Further investigation of the mouse tail DNA was performed 
using PCR with GPD1L cDNA primers specific for the transgene. The PCR results confirmed 
the negative results of the southern blot. The negative PCR results can be seen below in figure 
21. 
Table 3 PCR primers for transgene conformation: F & #1: 500 bp; F & #2: 800 bp 
Forward for set 1&2        5’-CCCAGCTGCCCGGCACTCTTA-3’ 
Reverse #1                       5’-CTTGTGTCCAGGAAGATATTT-3’ 
Reverse #2                         5’-ATGAGTCACAGGCGGATGACG-3’ 
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500 bp
500 bp
 
Figure 21 PCR of mouse tail DNA using the forward and reverse #1 
Well # 2-20 and 22-26 are the 24 wild type and well 27-40 are the14 mutants. All are negative for the presence 
of the GPD1L transgene. 
 
The pronuclear injection was performed again. At six weeks after injection, we received 
the first pups to test. Thirty-three offspring were produced from two litters for the wild type 
construct. Again, Kenneth Rahl extracted the tail DNA and performed another southern blot. Of 
the 33 pups in the litter there were ten that were positive for the presence of the transgene on the 
blot. As before all 33 DNA samples were tested by PCR using the primers specific for the 
Human GPD1L transcript above. The same ten positive tail samples showed a visible PCR 
product for the gene. Below is figure 22 are the PCR results for the wild type offspring. 
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A. 
 
B. 
 
C. 
 
Figure 22 Second pronuclear injection test PCR of wild type. 
Gels A and B show the results of the forward primer and reverse primer #1.Gels C and D show the results of 
the forward primer and reverse primer #2. 
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The offspring for the mutant GPD1L transgene was obtained one week after the wild 
type. There were 6 possible lines in this litter. The DNA was extracted and analyzed by southern 
blot analysis. The blot showed one positive mouse line for the mutant construct. PCR analysis 
was performed using the Human GPD1L primers to validate the southern blot results. One of the 
six mouse tail DNA samples produced a visible PCR band suggesting that the transgene was 
present. The transgenics was successful with the production of ten wild type GPD1L lines and 
one mutant GPD1L line. In figure 23 the PCR analysis shows the presence of the transgene in ten 
wild type offspring and one mutant offspring using the forward primer and reverse primer #1. 
500bp
500 bp
 
Figure 23 Mutant PCR 
This gel shows ten positive wild type lines on the top row and ten negative wild type lines. There is one 
positive mutant line on the bottom row out of six total lines. PCR was produced using the forward primer and 
the reverse primer #1. 
 
In summary, we were able to generate both wild type and mutant GPD1L transgenic mouse 
models and these mice can be used for future functional studies. 
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5.0  DISCUSSION 
The construction of the GPD1L over expression clones was a little more difficult then 
anticipated. The main problem was the α-MHCpBluescript II SK+ plasmid (MHC vector) used 
for the final vector of the construct. The MHC vector was the only one available to complete the 
project. This vector was important to the project because it had the MHC promoter (a common 
promoter found in heart tissue for tissue specific expression) and a poly-A signal within its 
transcript. Unfortunately, the available restriction sites were very limited and made the design 
difficult. The problem was that the MHC vector was designed for use in a project other than that 
of the GPD1L gene study. Cloning into the α-MHCpBluescript II SK+ plasmid also required the 
use of another vector, namely the pBK-CMV plasmid, which was one of the many extra steps 
that were involved in the cloning process. The other molecular techniques like blunt ending with 
the Klenow fragment and removing the active phosphates from the linear plasmid were very 
important in assuring that the cloning process ended in such a great success. For the future 
projects, including the design and engineering of transgenic constructs, a different final plasmid 
vector would be ideal. Possibly one that contains multiple restriction sites allowing a greater ease 
for the design and creation of a transgenic construct. The same MHC plasmid could be used 
again but only by first inserting a ready made DNA linker to introduce more restriction sites first. 
Another factor that was important in this project and probably in all future projects involving 
transgenics is the mutagenesis protocol. This technique was especially important when the 
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several attempts to produce the mutant final construct failed. This technique saved both time and 
money during this study. 
There are a few reasons why the first pronuclear injection may not have worked. One 
reason is that the transgenes expression could be potentially lethal to the developing embryo. 
However, in most successful pronuclear injections only about 10% of the offspring actually 
express the inserted transgene (11). This would suggest that at least one pup should have been 
produced with the transgene inserted in its genome without expression of the inserted gene. 
Lethality could still be a reason for no transgenic offspring if the random insertion of the 
transgene is close to or within another gene in the mouse genome. If this was the case the 
insertion could have altered gene expression of one or more genes and become potentially lethal 
to the developing embryo. Although there is a chance of this happening the opposite is of equal 
chance and a non-lethal insertion occurring. Another problem that is common to the pronuclear 
injection process is that a great many of the developing zygotes can be lysed during the injection 
and are subsequently lost during the process. One other possibility is that the integrity of the 
DNA was poor. To check the integrity of the DNA, the GPD1L clones were sequenced with 
BigDye terminator sequencing again. The results of the sequencing showed that the DNA 
sequences were unaltered and intact. The integrity of the DNA could also have been affected by 
the final cleanup process used before the injection. The Gel extraction method used on the Not I 
digested products may have greatly affected the integrity of the GPD1L DNA. The final Not 1 
RE digest was performed again but the products were not gel extracted with the Qiagen kit as 
before. Instead they were sent to the transgenic facility in the reaction tubes. The facility used a 
different technique that incorporated a specific column that had time and time again, proven to 
give them better success. The pronuclear injection was then performed again. The injection was a 
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success. The use of a special column proved to be a much better method than the gel extraction 
method. 
The study was overall a great success. The creation of the two over expression constructs 
will not only aid in the characterization of the novel GPD1L gene but they will provide the first 
Brugada Syndrome murine model. The importance of these mouse models to public health is 
how they will contribute to the study of cardiovascular disease (CVD). CVD is an important 
public health issue that claims the lives of millions of people each year. The Brugada syndrome 
is a form of CVD and a well known cause of sudden cardiac death. In the past decade many 
important advances have been made for the identification and characterization of this disease but 
successful therapeutic solutions are not available. The absence of successful medical intervention 
is partly due to the lack in identifying novel genes and mutations that lead to cardiac arrhythmia 
and sudden cardiac death. The GPD1L transgenic mice produced in this study will become a 
valuable tool to understand the electrophysiology and molecular mechanisms of this novel gene. 
The models will aid in improving diagnosis, assessment of prognosis and the possibility of 
therapeutic alternatives for this rare but deadly disease. 
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